



The first C-RAD Catalyst™ systems to a radiation therapy clinic in Denmark

C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The radiation therapy clinic at the Vejle Hospital in Denmark has ordered two C-RAD Catalyst systems to be installed at linear accelerators from Elekta.

The Catalyst™ is a next-generation high performance tracking system based on optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable clinicians to perform a real-time assessment of patient positioning errors before and during treatment delivery. Interfaces to major vendors ensure a completely integrated workflow.

To start with the Catalyst systems will be equipped with functionality for positioning and interfaces to Elekta Mosaiq. The two systems are planned to be installed end of 2012.

Erik Hedlund, CEO, C-RAD AB:

"At ESTRO meetings and when demonstrating the new innovative Catalyst system at clinics in Denmark there has been a great interest for the inter active and patented capabilities of the system especially when positioning breast cancer patients and for correction of posture errors. As a result C-RAD has received a first order of two Catalyst systems from the well-known Vejle Hospital in Denmark."

Bjarke Lundegaard Mortensen, Head of Medical Physics, Technical Practice, Vejle Hospital:

"In Vejle we think that the Catalyst systems offer a great possibility to improve the quality of our treatment for breast cancer. For the patients that receive radiation of the lymph nodes in the periclavicular region the position of the arms is crucial and we think that Catalyst can contribute to an improved patient positioning."

Martin Berg, Head of Medical Physics, Clinical Practice, Vejle Hospital:

"We have a long tradition for having great emphase on offering optimal treatment modalities for breast cancer patients. This improvement comes perfect in line with our decision of offering Deep Inspiration Breath Hold (DIBH) gating technique for all our left sided breast cancer patients a few years ago. Also for lung cancer patients we see a potential improvement, as some patients has lymph node involvement in the periclavicular region."

About Vejle Hospital:

Vejle Hospital is part of the Lillebaelt Hospital group situated around the strait of Lillebaelt. Vejle Hospital is one of the two centers offering radiotherapy in the Region of Southern Denmark with a population 1,200,000.

The radiotherapy facility was established in 1983 and has since then been expanded to six linacs.

Approximately 1,500 cancer patients per year receive radiotherapy treatment at Vejle Hospital which is an Elekta reference hospital for clinical work.

In May 2012 Vejle Hospital together with Elekta hosted an international conference with focus on advanced techniques in radiation therapy of breast cancer.

Research

- Bioeffect modelling for evaluation of radiotherapy treatment strategies at the individual patient level
- Diffusion weighted MRI for treatment response prediction
- The value of Deep Inspiration Breath Hold (DIBH) for breast cancer

Clinical focus

- Combined Intensity Modulated Radiation Therapy and Brachytherapy for rectal and anal cancer
- Deep Inspiration Breath Hold (DIBH) for breast cancer Radiation Therapy
- Image Guided Radiation Therapy (IGRT)
- Regional competence center for anal cancer Radiation Therapy

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries in Sweden; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD has own sales companies in Germany, USA and China. The headquarter of the group is located in Uppsala, Sweden. Numbers of employees are currently 22 people. The activities at C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is listed at Nasdaq Omx First North Premier. The company's Certified Advisor is Erik Penser Bankaktiebolag.